Hepatitis C and autoimmune hepatitis: What gets treated first?

Jen Jung Pan, Jeffrey S. Crippin

Research output: Contribution to journalReview articlepeer-review


The coexistence of chronic hepatitis C (CHC) and autoimmune hepatitis (AIH) creates a clinical dilemma. Histologic features may suggest the predominance of one versus the other. Nevertheless, histologic differences are not absolute. Immunosuppressive therapy may be used as frontline treatment for patients with predominant histologic features of AIH. In the absence of clinical and biochemical improvement, interferon should not be withheld and a trial of antiviral therapy should be considered. Interferon can be frontline therapy for patients with the overlap syndrome, if histologic features of CHC predominate, a low titer of autoantibodies is present, and coexistent autoimmune diseases are absent. No matter what treatment is offered, close monitoring during the course of treatment is a necessity.

Original languageEnglish
Pages (from-to)15-19
Number of pages5
JournalCurrent Hepatitis Reports
Issue number1
StatePublished - Feb 2010


  • Autoimmune hepatitis
  • Hepatitis C
  • Treatment


Dive into the research topics of 'Hepatitis C and autoimmune hepatitis: What gets treated first?'. Together they form a unique fingerprint.

Cite this